Key statistics
On Tuesday, AIM Vaccine Co Ltd (6660:HKG.HS) closed at 6.08, 53.92% above the 52 week low of 3.95 set on Sep 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.29 |
---|---|
High | 6.66 |
Low | 6.05 |
Bid | 6.08 |
Offer | 6.10 |
Previous close | 6.96 |
Average volume | 4.84m |
---|---|
Shares outstanding | 1.21bn |
Free float | 220.92m |
P/E (TTM) | -- |
Market cap | 8.43bn HKD |
EPS (TTM) | -1.06 HKD |
Data delayed at least 15 minutes, as of Oct 15 2024 09:09 BST.
More ▼
Announcements
- The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration
- Application for clinical trial of AIM Vaccine’s human diploid rabies vaccine
- AIM Vaccine’s 13-valent pneumonia conjugate vaccine obtained Production license
- AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
- Phase III clinical data of AIM Vaccine iterative serum-free rabies vaccine reaches preset goals
- The bull market of innovative drug technology is booming, and the leading stock AIM Vaccine has erupted upward
More ▼